Individuals with COVID-19 who have undergone solid organ transplant (SOT) experience higher mortality and prolonged viral shedding compared with the general population.1-5 Multiple vaccine platforms have been proven successful in reducing viral spread and preventing poor outcomes in the general population.6-8Unfortunately, recipients of SOT were excluded from the initial licensing trials of these vaccines, and accumulating data have shown reduced immunogenicity among recipients of SOT.9-14

Facilitamos acceso al documento completo a través del siguiente enlace:


Deja una respuesta

Your email address will not be published.